- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arvinas Inc (ARVN)
Arvinas Inc stock price live, this page displays NASDAQ ARVN stock exchange data. View the ARVN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arvinas Inc real time stock price chart below.
What Is the Arvinas Inc Stock Price Today?
The Arvinas Inc stock price today is 10.44.
What Is the Stock Symbol for Arvinas Inc?
The stock symbol for Arvinas Inc is "ARVN."
What Stock Exchange Does Arvinas Inc Trade On?
Arvinas Inc is listed and trades on the NASDAQ stock exchange.
Is Arvinas Inc a Good Stock to Buy?
Determining whether Arvinas Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARVN quote. (ISIN: US04335A1051) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
What Is the Arvinas Inc Stock Price Today?
The Arvinas Inc stock price today is 10.44.
What Is the Stock Symbol for Arvinas Inc?
The stock symbol for Arvinas Inc is "ARVN."
What Stock Exchange Does Arvinas Inc Trade On?
Arvinas Inc is listed and trades on the NASDAQ stock exchange.
Is Arvinas Inc a Good Stock to Buy?
Determining whether Arvinas Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARVN quote. (ISIN: US04335A1051) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
Fair Value
An estimate of a Arvinas's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.15
10.52
52 wk Range
5.90
14.51
Earnings results expected in 4 days
1/2
Fair Value
An estimate of a Arvinas's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.1510.52
52 wk Range
5.9014.51
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARVN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Arvinas's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
14.88
Upside
+42.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Arvinas Inc SWOT Analysis
Vepdegestrant's Promise | Explore vepdegestrant's potential as a first-in-class oral PROTAC for ESR1-mutant breast cancer patients, with promising efficacy in recent trials |
Financial Crossroads | Delve into Arvinas's strategic restructuring and financial outlook, balancing cost-cutting measures with a healthy cash position and extended runway |
Market Dynamics | Learn about the challenges Arvinas faces in the competitive oral SERD market, with analyst price targets ranging from $10 to $48 |
Platform Potential | Discover the broader implications of Arvinas's PROTAC platform technology, offering opportunities beyond vepdegestrant in addressing "undruggable" proteins |
Arvinas Inc Earnings Call Summary for Q4/2025
- Q4 2025 EPS of -$1.10 missed forecast of -$0.51 by 115.69%; revenue of $9.5M fell 74.27% short of $36.92M estimate, triggering 6.5% stock decline.
- Revenue plunged 83.9% year-over-year due to $40.3M reduction from Novartis license agreement; cash reserves stand at $685.1M, down 32.1%.
- Operating expenses decreased with R&D spending down 26.7% to $61.1M and G&A costs down 32.6% to $23.0M as part of cost-cutting measures.
- Company maintains cash runway guidance into second half of 2028, focusing investments on clinical programs with key trial data expected in 2026.
- Stock fell to $11.50 in pre-market despite 68% six-month gain; executives emphasized strategic focus on neurology and oncology pipeline advancement.
Last Updated: 24/02/2026, 15:44
Read Full TranscriptCompare ARVN to Peers and Sector
Metrics to compare | ARVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.3x | −9.1x | −0.4x | |
PEG Ratio | −0.14 | 0.15 | 0.00 | |
Price/Book | 1.5x | 3.6x | 2.6x | |
Price / LTM Sales | 2.5x | 17.9x | 3.2x | |
Upside (Analyst Target) | 48.5% | 40.3% | 46.2% | |
Fair Value Upside | Unlock | −3.1% | 7.2% | Unlock |
Analyst Ratings
10 Buy
8 Hold
1 Sell
Ratings:
19 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 14.88
(+42.48% Upside)
Earnings
Latest Release
Feb 24, 2026
EPS / Forecast
-1.10 / -0.51
Revenue / Forecast
9.5M / 36.92M
People Also Watch
FAQ
What Is the Arvinas (ARVN) Stock Price Today?
The Arvinas stock price today is 10.44 USD.
What Stock Exchange Does Arvinas Trade On?
Arvinas is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Arvinas?
The stock symbol for Arvinas is "ARVN."
What Is the Arvinas Market Cap?
As of today, Arvinas market cap is 667.75M USD.
What Is Arvinas's Earnings Per Share (TTM)?
The Arvinas EPS (TTM) is -1.14.
When Is the Next Arvinas Earnings Date?
Arvinas will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is ARVN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Arvinas Stock Split?
Arvinas has split 0 times.
How Many Employees Does Arvinas Have?
Arvinas has 246 employees.
What is the current trading status of Arvinas (ARVN)?
As of Apr 26, 2026, Arvinas (ARVN) is trading at a price of 10.44 USD, with a previous close of 10.42 USD. The stock has fluctuated within a day range of 10.15 USD to 10.52 USD, while its 52-week range spans from 5.90 USD to 14.51 USD.
What Is Arvinas (ARVN) Price Target According to Analysts?
The average 12-month price target for Arvinas is 14.88 USD, with a high estimate of 21 USD and a low estimate of 6 USD. 10 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +42.48% Upside potential.
What Is the ARVN Premarket Price?
ARVN's last pre-market stock price is 10.50 USD. The pre-market share volume is 4,870.00, and the stock has decreased by 0.08, or 0.77%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.